Mirum Pharmaceuticals, Inc. (MIRM) Stock: Price, Forecast & Analyst Target
Mirum Pharmaceuticals, Inc. (MIRM) — MoonshotScore 14/100 (Weak band), calculated Oct 5, 2026. Price $82.93 (-1.18%), as of the Oct 2, 2026 trading session; market cap $5.06B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 11.54× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 3, 2026
Mirum Pharmaceuticals, Inc. · MIRM · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Mirum Pharmaceuticals develops therapies for rare, inherited liver diseases where few alternatives exist. The company has one commercial drug generating revenue and a second in development, but both remain in early regulatory and clinical stages. Success or failure depends almost entirely on FDA decisions and clinical trial outcomes, not market share or operational efficiency.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Mirum Pharmaceuticals (MIRM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, though quality and the balance sheet are only middling. Business Quality: Average; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $176M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z -0.64 · Piotroski F 3
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 15 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak |
The score was 14 in the stored Oct 4, 2026 snapshot and remains 14 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $82.93 |
| Change on the day | -1.18% |
| 52-week range | $63.23–$130.00 |
| Market capitalisation | $5.06B |
| Price / earnings (trailing) | -181.90 |
| Shares traded on the day | 1.13M |
| Beta (volatility vs the S&P 500) | 0.49 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Mirum Pharmaceuticals (MIRM): Bearish Lean
33/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the MIRM film — every key number, told as a short cinematic story
~2 min · open the film
What is Mirum Pharmaceuticals (MIRM), and what does it report?
Short answer · as of
Mirum is a biopharmaceutical firm with a single product on the market—LIVMARLI, an oral treatment for progressive familial intrahepatic cholestasis and related cholestatic liver diseases.
Research dated 2026-09-13.
Mirum is a biopharmaceutical firm with a single product on the market—LIVMARLI, an oral treatment for progressive familial intrahepatic cholestasis and related cholestatic liver diseases. The company sells this drug while simultaneously conducting trials for bile acid modulators in pregnancy-related and autoimmune liver conditions. Revenue comes from LIVMARLI sales; costs are almost entirely research and development staff trying to bring the second drug to the market.
The reported numbers reflect a company at an inflection point. Quarterly revenue has grown steadily since the drug launched, but operating expenses dwarf sales because the second program demands a full research workforce. The income statement shows deepening losses on a generally expanding revenue base, which is typical for early commercialization of a specialty rare-disease therapy.
What do the latest results show for Mirum Pharmaceuticals (MIRM)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $176M.
Research dated 2026-09-13.
The most recent quarter showed revenue growth, with gross margins above realistic levels for a specialty pharma despite fixed manufacturing costs. Operating losses widened, however, as research intensity increased in preparation for regulatory submissions. Cash flow deteriorated sharply in the same period, driven both by higher operating burn and by the timing of cash receipts and payables—a temporary pattern, but one that compounds when runway is already finite.
Analyst revisions have been volatile, suggesting uncertainty about trial timelines and commercial ramp. The most recent earnings report surprised to the downside on per-share loss, though revenue itself met guidance, indicating that cost controls slipped rather than sales momentum failed.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $176.24M Jun 30, 2026
- Latest quarter · R&D
- $90.53M Jun 30, 2026
- Latest quarter · SG&A
- $81.47M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$42.54M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $176.24M | $90.53M | $81.47M | −$42.54M |
| Mar 31, 2026 | $159.88M | $97.91M | $96.33M | −$63.16M |
| Dec 31, 2025 | $148.93M | $51.11M | $74.13M | −$4.57M |
| Sep 30, 2025 | $133.01M | $42.96M | $61.91M | $2.60M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $176.20M Aug 5, 2026
- Latest report · revenue estimate
- $166.33M Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $176.20M | $166.33M | −$1.0600 | −$0.7425 |
| May 6, 2026 | $159.90M | $148.21M | −$13.4300 | −$0.4000 |
| Feb 25, 2026 | $148.93M | $142.50M | −$0.1100 | $0.0200 |
| Nov 4, 2025 | $133.01M | $140.88M | $0.0500 | −$0.1000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $176M | -$67M | -$1.06 (diluted) |
| Q1 FY2026 | $160M | -$790M | -$13.43 (diluted) |
| Q4 FY2025 | $149M | -$6M | -$0.12 (diluted) |
| Q3 FY2025 | $133M | $3M | $0.05 (diluted) |
What are the financial strengths and risks for Mirum Pharmaceuticals (MIRM)?
Short answer
Cash and short-term investments were $438.29M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$273.01M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Mirum holds enough cash and short-term investments to fund operations for roughly another year and a half, a runway that extends into the period when regulatory decisions on the second drug become likely. The balance sheet shows strong liquidity ratios, meaning the company can cover near-term obligations easily. Debt is modest relative to cash, and the company carries no catastrophic lease or pension obligations.
The central risk is not balance-sheet fragility but clinical and regulatory outcomes. If trials succeed and the FDA approves, the company moves to profitability quickly under analyst models. If trials stall or regulators demand more data, the company exhausts cash before generating enough revenue to sustain itself. Insiders have not purchased shares in the past half-year despite what would normally be attractive valuations after a recent price decline, a signal that insiders expect uncertainty to persist.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$273.01M Jun 30, 2026
- Previous quarter · operating cash flow
- −$228.76M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$273.01M | −$690,000 |
| Mar 31, 2026 | −$228.76M | −$660,000 |
| Dec 31, 2025 | $6.07M | −$600,000 |
| Sep 30, 2025 | $39.68M | −$190,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Mirum Pharmaceuticals (MIRM)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026.
Research dated 2026-09-13.
The next material event is the FDA's response to pending submissions for LIVMARLI in additional indications and for Volixibat. Approval dates should be disclosed within the coming quarters. Commercial scaling, if approved, will move from aspirational to observable in pricing discussions and insurance negotiation announcements.
Analyst estimates project profitability within several years, conditional on both drugs reaching the market and capturing expected pricing. Each trial readout, regulatory decision, and quarterly revenue update will either validate or undermine these assumptions. The company also faces the question of whether cash on hand suffices to reach break-even, or whether a financing round becomes necessary before then.
How does Mirum Pharmaceuticals compare with its peers?
Short answer
Mirum Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Rare-disease biotech operates on a fundamentally different model than broad-market pharmaceutical companies. Success is not about market share or competitive pricing; it is about regulatory approval and patient identification in a small population. Mirum has no generic or biosimilar competitors and faces no price pressure from volume alone—the limiting constraint is FDA acceptance and insurance coverage.
Compared to other rare-disease companies at similar clinical and commercial stages, Mirum's cash runway and burn rate are within normal bounds. Unlike early-stage pure biotech firms without approved drugs, Mirum has proof of commercial demand through LIVMARLI sales. Unlike large pharmaceutical corporations, it carries no legacy costs, no portfolio diversification, and no defensive marketing burden. The difference is not quality but structure: Mirum succeeds or fails on a single therapeutic area and a handful of clinical programs.
| Company | Price | Market value | Score |
|---|---|---|---|
| $301.72 Oct 5, 2026 | $6.07B | 96 5-pillar Oct 5, 2026 | |
| $46.41 Oct 5, 2026 | $3.66B | 96 5-pillar Oct 5, 2026 | |
| $29.34 Oct 5, 2026 | $8.00B | 89 5-pillar Oct 5, 2026 | |
| $24.70 Oct 5, 2026 | $3.15B | 88 5-pillar Oct 5, 2026 | |
| $19.89 Oct 5, 2026 | $3.42B | 76 5-pillar Oct 5, 2026 | |
| $45.39 Oct 5, 2026 | $3.36B | 73 5-pillar Oct 5, 2026 | |
| $156.53 Oct 5, 2026 | $6.40B | 69 5-pillar Oct 5, 2026 | |
| $82.63 Oct 5, 2026 | $5.10B | 68 5-pillar Oct 5, 2026 | |
| $41.18 Oct 5, 2026 | $4.45B | 66 5-pillar Oct 5, 2026 | |
| $27.45 Oct 5, 2026 | $3.09B | 66 5-pillar Oct 5, 2026 | |
| $54.17 Oct 5, 2026 | $8.31B | 65 5-pillar Oct 5, 2026 | |
| $116.34 Oct 5, 2026 | $4.88B | 64 5-pillar Oct 5, 2026 | |
| Mirum Pharmaceuticals (MIRM) — this page | $82.93 | $5.06B | 14 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $130.00 – $195.00
- Consensus target
- $147.10
- Median target
- $141.00
Consensus record · Captured .
Measured against a quoted price of $82.93 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 76
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 32
- Other transactions
- 44
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 338 Period end Jun 30, 2026
- Previous quarter · holders
- 318 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Frazier Life Sciences Management, L.P. | 7,679,684 |
| Jupiter Topco LLC | 5,909,184 |
| Blackrock, INC. | 4,390,063 |
| Fmr LLC | 3,670,314 |
| Price T Rowe Associates INC /Md/ | 2,655,607 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is LIVMARLI and when did it launch?
LIVMARLI is an oral therapy for inherited cholestatic liver disease, the only approved drug in its class for progressive familial intrahepatic cholestasis. The company has been commercializing it and expanding clinical trials to additional disease conditions where the same mechanism may apply.
How much longer can the company operate without profitability?
Mirum's current cash and investments support operations for roughly another year and a half if burn rates remain stable. This window aligns with expected regulatory and trial readout timelines, but does not provide margin for delays. If trials slow or FDA decisions take longer than anticipated, the company may require additional financing.
Why are insiders selling shares?
Insiders have executed restricted stock vesting and have sold shares in the open market, a pattern consistent with tax-withholding and diversification rather than distress sales. However, the absence of any insider purchases in the past half-year suggests no conviction that the current valuation offers sufficient margin of safety to warrant personal investment.
What is the single biggest uncertainty for this stock?
FDA approval decisions and clinical trial outcomes for both LIVMARLI extensions and Volixibat will determine whether Mirum reaches sustainable profitability or exhausts cash and must dilute shareholders. Investors have no way to predict or control these outcomes; they can only wait for reports and trial readouts. The company's success or failure is binary in a way that operational improvements cannot remedy.
What is the MIRM stock price today?
The last price recorded on this page for Mirum Pharmaceuticals, Inc. (MIRM) is $82.93, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MIRM price target?
The analyst consensus price target for Mirum Pharmaceuticals, Inc. (MIRM) is $147.10 (range $130.00 to $195.00, median $141.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (79 figures)
The 79 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, 94404 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "989 East Hillsdale Boulevard, Foster City, CA, 94404, US". |
FMP — 71 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $82.93 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:14:20.930Z. | |
px.change | Change on the day | -1.18% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.06B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T21:14:19.875Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.99 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $176M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $63.23–$130.00 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | -181.90 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.13M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.49 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Christopher Peetz | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 433 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $19.14M, net result −$83.99M; FY2022 revenue $77.06M, net result −$135.66M; FY2023 revenue $186.37M, net result −$163.41M; FY2024 revenue $336.89M, net result −$87.94M; FY2025 revenue $521.31M, net result −$23.36M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Product $521.31M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 81.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $176.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $90.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $81.47M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$42.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $159.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $97.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $96.33M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$63.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $148.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $51.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $74.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$4.57M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $133.01M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $42.96M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $61.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $2.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $176.20M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $166.33M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | −$1.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | −$0.7425 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_actual | Revenue · reported — report date 2026-05-06 | $159.90M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.revenue_estimated | Revenue · estimate — report date 2026-05-06 | $148.21M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_actual | EPS · reported — report date 2026-05-06 | −$13.4300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-06.eps_estimated | EPS · estimate — report date 2026-05-06 | −$0.4000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.revenue_actual | Revenue · reported — report date 2026-02-25 | $148.93M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.revenue_estimated | Revenue · estimate — report date 2026-02-25 | $142.50M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.eps_actual | EPS · reported — report date 2026-02-25 | −$0.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-25.eps_estimated | EPS · estimate — report date 2026-02-25 | $0.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $133.01M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $140.88M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.0500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | −$0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $438.29M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$273.01M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $123.03M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $760.54M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$273.01M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$228.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$690,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$660,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $6.07M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$600,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $39.68M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$190,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $130.00 – $195.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $147.10 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $141.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 76 transactions · 0 purchases, 32 sales, 44 other transactions · 12 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 338 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 318 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Frazier Life Sciences Management, L.P. — shares in provider snapshot | 7,679,684 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Jupiter Topco LLC — shares in provider snapshot | 5,909,184 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 4,390,063 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Fmr LLC — shares in provider snapshot | 3,670,314 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 2,655,607 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -0.64 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 11.54× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $438.29M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($176.20M) with the recorded estimate ($166.33M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$1.0600) with the recorded estimate (−$0.7425) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 14 of 100 · Weak · pillars 44 / 42 / 45 / 87 / 44 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 14 (stored snapshot Oct 4, 2026) → 14 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-06.revenue_actual,earn.history.depth.2026-05-06.revenue_estimated,earn.history.depth.2026-05-06.eps_actual,earn.history.depth.2026-05-06.eps_estimated,earn.history.depth.2026-02-25.revenue_actual,earn.history.depth.2026-02-25.revenue_estimated,earn.history.depth.2026-02-25.eps_actual,earn.history.depth.2026-02-25.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Legal name | Mirum Pharmaceuticals, Inc. | 2026-02-25 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-25 |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Employees | Count: 433 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-05 | FMP | Financial Modeling Prep (FMP) earnings |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash runway cross-check (ours) | Years: 1.9; Method: cash and short-term investments of $438.3M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($229.8M per year); Reaches: 2028-05; Cash basis: cash and short-term investments; Cash: $438.30M; Annualized cash use: $229.80M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Insider transactions, last 180 days | Net shares: -117,798; Window days: 180; Price low: $2.94; Clustered days: 2026-06-15; Price high: $124.94; Buy transactions: 0; Distinct insiders: 12; Sell transactions: 28; Other transactions: 32; Total transactions: 60; Other transaction types: A-Award: 16, M-Exempt: 16; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-02 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Trailing twelve-month ratio set | Quick ratio: 2.74; Current ratio: 2.86; Debt to equity: -72.97; Net margin: -139.2%; Gross margin: 81.7%; Operating margin: -17.4%; Return on assets: -82.3%; Return on equity: -410.2% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-11-03; EPS estimate: -$0.52558 per share; Revenue estimate: $178.06M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Recent SEC filings |
| 2026-09-08 | OFFICIAL | SEC EDGAR filer submissions |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-27 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Institutional ownership (13F) | Holders: 338; Quarter: 2026-06-30; Holders previous quarter: 318 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Revenue by segment | Product: $521.31M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
Data provided for informational purposes only.
ETFs that hold MIRM
Funds in our ETF coverage that list MIRM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| State Street SPDR S&P Biotech ETF (XBI) | 1.41% | |
| Federated Hermes MDT Small Cap Core ETF (FSCC) | 1.31% |